The designation LDH-AL6A Activators refers to a specialized class of chemical compounds that interact with a specific enzyme or protein purportedly denoted by LDH-AL6A. The acronym LDH typically stands for lactate dehydrogenase, a well-studied enzyme that plays a key role in cellular metabolism, particularly in the interconversion of lactate and pyruvate. As such, without clear reference to a defined enzyme or protein, it is challenging to provide a detailed description of the activators for LDH-AL6A. Nonetheless, the concept of enzyme activators is a well-established area of biochemistry; they are compounds that increase the activity of enzymes by binding to them. These activators can exert their effect by stabilizing an active conformation of the enzyme, enhancing substrate binding, or modifying the enzyme's dynamics in a manner that increases its catalytic efficiency. Their action may be allosteric, where the activator binds at a site distinct from the active site, or orthosteric, where the activator interacts directly with the active site or catalytic residues.
If LDH-AL6A were to represent a specific enzyme variant or a protein with distinct catalytic properties, the development of activators for this enzyme would necessitate a comprehensive understanding of its structure and function. Structural biology techniques, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, would be pivotal in revealing the three-dimensional conformation of the enzyme, including the active site and potential allosteric sites. Such knowledge would enable targeted design of molecules that can bind to these sites and modulate the enzyme's activity. Biochemical assays would be employed to assess the impact of these molecules on the enzyme's activity, measuring parameters such as reaction velocity, substrate affinity, and overall catalytic efficiency. The process of identifying and optimizing LDH-AL6A activators would likely involve a cyclic process of design, synthesis, and testing, utilizing computational chemistry for molecular modeling and predictions, followed by empirical validation in the laboratory to fine-tune the activator's efficacy and specificity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium dichloroacetate | 2156-56-1 | sc-203275 sc-203275A | 10 g 50 g | $55.00 $209.00 | 6 | |
May shift metabolism from glycolysis to glucose oxidation, potentially upregulating LDHAL6A as a compensatory response. | ||||||
Oxamic acid | 471-47-6 | sc-250620 | 25 g | $148.00 | ||
Competitive inhibitor of LDH, which could lead to an increase in LDHAL6A expression to compensate for inhibited LDH activity. | ||||||
1,1-Dimethylbiguanide, Hydrochloride | 1115-70-4 | sc-202000F sc-202000A sc-202000B sc-202000C sc-202000D sc-202000E sc-202000 | 10 mg 5 g 10 g 50 g 100 g 250 g 1 g | $20.00 $43.00 $63.00 $156.00 $260.00 $510.00 $31.00 | 37 | |
An AMPK activator that alters metabolism, possibly upregulating LDHAL6A as part of metabolic reprogramming. | ||||||
Phenformin Hydrochloride | 834-28-6 | sc-219590 | 10 g | $119.00 | 4 | |
Another AMPK activator with effects on metabolism, which may similarly induce LDHAL6A expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A polyphenol that can modulate metabolic pathways, potentially affecting LDHAL6A expression. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glycolysis inhibitor that might induce the expression of alternative glycolytic enzymes such as LDHAL6A. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
Mimics hypoxia and may upregulate hypoxia-inducible factors, potentially leading to increased LDHAL6A expression. | ||||||
Hypoxanthine | 68-94-0 | sc-29068 | 25 g | $69.00 | 3 | |
A purine derivative that can increase in hypoxic conditions, possibly affecting LDHAL6A expression. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates AMPK and can lead to metabolic changes, potentially increasing LDHAL6A expression. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
A PPAR-gamma agonist, affects glucose metabolism, and could potentially induce LDHAL6A expression. | ||||||